Indacaterol + Control

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

Conditions

Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

Trial Timeline

Feb 1, 2013 โ†’ Sep 1, 2014

About Indacaterol + Control

Indacaterol + Control is a phase 3 stage product being developed by Novartis for Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01778062. Target conditions include Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01778062Phase 3Completed

Competing Products

20 competing products in Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + Epoetin betaChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
FK949EAstellas PharmaPhase 1
33
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
ASP8825Astellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP7991Astellas PharmaPhase 1
33
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
ATG-FAstellas PharmaApproved
85
CelecoxibAstellas PharmaPre-clinical
23
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 1
33